Medivation, Inc. (NASDAQ:MDVN) reported its financial results for the second quarter ended June 30, 2011. “We and our partner Astellas continue to work diligently toward our goal of developing MDV3100 across the spectrum of advanced prostate cancer disease states, and are pleased to announce that we expect to report interim analysis data from our post-chemotherapy Phase 3 AFFIRM trial this year,” said David Hung, M.D., president and chief executive officer of Medivation.
Read more at: http://crwewallstreet.com/?p=20941